Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips

AN2 Therapeutics stock is down on Friday after ANTX investors learned of the company terminating its EBO-301 Phase 2/3 clinical trial.

The post Why Is AN2 Therapeutics (ANTX) Stock Down 35% Today? appeared first on InvestorPlace.

• Legendary Investor Predicts: “Forget AI... THIS Technology Is the Future”